Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Anthony Child

Showing results (21-30 of 44) with videos related to

Pageof 5
Sort By:
BMC Nephrology|July 18, 2018
Serum free light chain levels and renal function at diagnosis in patients with multiple myelomaPunit Yadav, Paul Cockwell, Mark Cook, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 8, 2010
Heterogeneity in the prognostic significance of 12p deletion and chromosome 5 amplification in multiple myelomaWilliam Tapper, Laura Chiecchio, Gian Paolo Dagrada, et al.
Blood Advances|July 5, 2022
Clinical characteristics and outcomes of IgD myeloma: experience across UK national trialsCharles Agbuduwe, Gulnaz Iqbal, David Cairns, et al.
The Lancet. Haematology|November 18, 2017
Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort studyJohn P Campbell, Jennifer L J Heaney, Sankalp Pandya, et al.
Oncogene|February 20, 2003
Genomic characterization of the chromosomal breakpoints of t(4;14) of multiple myeloma suggests more than one possible aetiological mechanismJames A L Fenton, Guy Pratt, Andy C Rawstron, et al.
The Lancet. Haematology|February 11, 2019
A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation studyGordon Cook, Kara-Louise Royle, Charlotte Pawlyn, et al.
Haematologica|October 17, 2015
Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimenRuth M de Tute, Andy C Rawstron, Walter M Gregory, et al.
Blood|August 27, 2013
The impact of response on bone-directed therapy in patients with multiple myelomaAlessandra Larocca, J Anthony Child, Gordon Cook, et al.
Blood|April 16, 2014
Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcomeAnnamaria Brioli, Hannah Giles, Charlotte Pawlyn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 14, 2011
Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survivalKevin D Boyd, Fiona M Ross, Brian A Walker, et al.
Pageof 5

Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
BMC Nephrology|July 18, 2018
Serum free light chain levels and renal function at diagnosis in patients with multiple myelomaPunit Yadav, Paul Cockwell, Mark Cook, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 8, 2010
Heterogeneity in the prognostic significance of 12p deletion and chromosome 5 amplification in multiple myelomaWilliam Tapper, Laura Chiecchio, Gian Paolo Dagrada, et al.
Blood Advances|July 5, 2022
Clinical characteristics and outcomes of IgD myeloma: experience across UK national trialsCharles Agbuduwe, Gulnaz Iqbal, David Cairns, et al.
The Lancet. Haematology|November 18, 2017
Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort studyJohn P Campbell, Jennifer L J Heaney, Sankalp Pandya, et al.
Oncogene|February 20, 2003
Genomic characterization of the chromosomal breakpoints of t(4;14) of multiple myeloma suggests more than one possible aetiological mechanismJames A L Fenton, Guy Pratt, Andy C Rawstron, et al.
The Lancet. Haematology|February 11, 2019
A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation studyGordon Cook, Kara-Louise Royle, Charlotte Pawlyn, et al.
Haematologica|October 17, 2015
Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimenRuth M de Tute, Andy C Rawstron, Walter M Gregory, et al.
Blood|August 27, 2013
The impact of response on bone-directed therapy in patients with multiple myelomaAlessandra Larocca, J Anthony Child, Gordon Cook, et al.
Blood|April 16, 2014
Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcomeAnnamaria Brioli, Hannah Giles, Charlotte Pawlyn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 14, 2011
Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survivalKevin D Boyd, Fiona M Ross, Brian A Walker, et al.
Pageof 5